Oppenheimer Begins Coverage on Savara (NASDAQ:SVRA)

Equities researchers at Oppenheimer assumed coverage on shares of Savara (NASDAQ:SVRA) in a note issued to investors on Friday. The firm set an “outperform” rating and a $11.00 price target on the stock. Oppenheimer’s price target would indicate a potential upside of 114.84% from the company’s previous close.

A number of other research firms have also issued reports on SVRA. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Tuesday. William Blair set a $10.00 price objective on shares of Savara in a research note on Monday, March 16th. HC Wainwright reiterated a “buy” rating on shares of Savara in a research report on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.13.

Savara Trading Up 3.6%

Shares of SVRA opened at $5.12 on Friday. The business’s 50-day moving average price is $5.50 and its 200 day moving average price is $5.35. The company has a current ratio of 11.85, a quick ratio of 11.85 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.05 billion, a P/E ratio of -9.66 and a beta of 0.32. Savara has a 1-year low of $1.89 and a 1-year high of $7.01.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Analysts expect that Savara will post -0.48 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Large investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in shares of Savara by 10.8% during the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after purchasing an additional 16,634 shares during the period. Prudential Financial Inc. acquired a new position in Savara in the 2nd quarter valued at approximately $30,000. XTX Topco Ltd acquired a new position in Savara in the 2nd quarter valued at approximately $201,000. Invesco Ltd. lifted its position in Savara by 35.4% in the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock worth $276,000 after buying an additional 31,633 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Savara by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after buying an additional 6,449 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.